A Phase 3 interventional study of Atacand/HCT, Caduet and GENESISTM Embolic Protection Stent and Angioguard Device (Angioplasty plus stenting) in Atherosclerosis, Cardiovascular Diseases and Hypertension, Renovascular, sponsored by Baim Institute for Clinical Research. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-10-05.
Sponsored by Baim Institute for Clinical Research · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 468 studies in Atherosclerosis with a site in United States — 47 open to participants now, 75 under way, 17 of them phase 3. Atherosclerosis · United States.
Among the 468 studies in Atherosclerosis with a site in United States, this one is the 51st largest by enrollment of the 328 interventional ones that give a count, is one of 18 that started in 2004, is one of 61 in phase 3, and was the 40th registered.
1,519 studies on the registry are indexed under Atherosclerosis; 226 are open to participants now.
Browse Atherosclerosis studies →47 of the 468 studies in Atherosclerosis with a site in United States are open now. Recruiting first, the newest first:
University of Colorado, Denver · Sites in United States
Ages 55+
Verve Therapeutics, Inc. · Sites in United States
Ages 18–70
St. Jude Children's Research Hospital · Sites in United States
Ages 18+
Eli Lilly and Company · Sites in United States, Argentina, Japan and 1 more country
Ages 18+
Washington University School of Medicine · Sites in United States
Ages 18+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 163 Atherosclerosis studies recruiting now, 85 (52%) set no upper age limit and 34 (21%) stop at 75 or younger; 16 take children under 18; 35 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
468 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 46 · Phase 2 84 · Phase 3 74 · Phase 4 45
First in 1973; this study’s year is marked. 18 started in 2004.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 947 is above the median of 100 across 881 interventional studies indexed under Atherosclerosis.
Median enrollment 119 across the 328 interventional studies, 170 across the 137 observational. Of the 366 that completed or were terminated, 134 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
141 of 468 have an industry lead sponsor. The 10 most frequent:
Baim Institute for Clinical Research is the lead sponsor of 10 studies on the registry; 3 are open to participants now.
Baim Institute for Clinical Research has 1 study filed under Atherosclerosis — fewer than ten, so there is no comparison to draw.
23 of the studies in Atherosclerosis with a site in United States that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05202509Phase 3NewAmsterdam PharmaCardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease | 2026-11 |
| NCT07000123Phase 3AstraZenecaA Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With Clinical ASCVD or at Risk for a First ASCVD Event | 2027-01-11 |
| NCT05132439Phase 3VA Office of Research and DevelopmentMetfOrmin BenefIts Lower Extremities With Intermittent Claudication | 2027-02-28 |
| NCT05030428Phase 3Novartis PharmaceuticalsStudy of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease | 2027-05-10 |
| NCT07121010University of PittsburghHow Animal and Plant Protein Shakes Change the Body's Nutrient and Health Responses | 2026-12 |
Add all 23 to your calendar (.ics) → With an account.
Among the 468 studies in Atherosclerosis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will compare medical therapy plus stenting of hemodynamically significant renal artery stenoses versus medical therapy alone in patients with systolic hypertension and renal artery stenosis.
BACKGROUND:
Atherosclerotic renal artery stenosis is a common problem for which there is no clear consensus on diagnosis or therapy. There likely exists a progression in which renal ischemia leads to neuroendocrine activation, hypertension, and renal insufficiency resulting in acceleration of atherosclerosis, further renal dysfunction, and development of left ventricular hypertrophy. These events in turn lead to adverse clinical events.
Renal artery stenosis is one of the two major known causes of hypertension and occurs in 1-5% of hypertensive patients. In patients with accelerated hypertension, the prevalence of renal artery stenosis is much higher, ranging from 10-40%. Renal artery stenosis, when occurring bilaterally, or in a solitary kidney, is a significant cause for end-stage renal disease, accounting for several percent of patients with end-stage renal disease. Clinically, atherosclerotic renal artery stenosis is a major problem primarily in older patients, and is often seen in long-standing hypertensives whose blood pressure becomes very difficult to control. Of major significance is the progressive nature of atherosclerotic renal artery stenosis, progressing at the rate of about 10% per year (45-60% progression rate in 4-7 year follow-ups). Over this time period, 10-15% of patients develop total renal artery occlusion. If the renal artery stenosis is greater than 75% when detected, 40% of patients develop total occlusion. Due to the progressive nature of atherosclerotic lesions, the decline in renal function in some individuals, and difficult-to-control hypertension, the medical community has sought to detect those patients in whom intervention would be beneficial. This has been extremely difficult to achieve and tests to date have not been uniformly predictive, including peripheral vein plasma renin activity, renal vein renin activity, captopril-stimulated nuclear medicine renal scans, etc.
Since approximately 50% of patients with unilateral renal artery stenosis of significant degree (definitions vary) benefit from surgical intervention, enthusiasm has continued with the advent of renal artery angioplasty. The entire field is moving very quickly. However, there are neither current data nor prospective studies indicating the benefit of renal artery angioplasty plus stents. Studies over the last decade have shown that balloon angioplasty alone is associated with a high rate of recurrence in patients with atherosclerotic renal artery stenosis. In the present climate, there is great enthusiasm to perform angioplasty plus stent placement in atherosclerotic renal artery stenosis, without supporting data for efficacy compared to medical management alone. Angioplasty and stent placement in the renal arteries had been the domain of interventional radiologists, but recently, interventional cardiologists are also performing these procedures. The questions as to who will benefit from intervention and which intervention to use have not been answered. Renal artery angioplasty and stent placement subjects the patient to procedural risks, as well as increased cost, when compared to aggressive antihypertensive medication and risk factor medication and therapy.
DESIGN NARRATIVE:
This randomized, multicenter clinical trial will contrast the effect of optimal medical therapy alone to stenting with optimal medical therapy, on a composite of cardiovascular and renal endpoints: cardiovascular or renal death, myocardial infarction, hospitalization for congestive heart failure, stroke, doubling of serum creatinine level, and need for renal replacement therapy. These endpoints will be evaluated by a clinical events committee masked to treatment assignment. The secondary endpoints will 1) evaluate the mechanisms linked to clinical events; 2) describe differential effectiveness in critical end-organs; 3) determine the value of stenting from the patient and the health policy perspectives, measured as quality of life and cost-effectiveness; and 4) evaluate for clinically relevant differences in treatment effectiveness within the primary endpoint.
Patients will undergo a baseline evaluation to determine eligibility. Approximately 1,080 patients will be randomized to optimal medical therapy alone or to stenting with optimal medical therapy at an estimated 100 clinical sites. Initially, patients will be followed at 2-week intervals, until blood pressure is at target or up to 2 months. Follow-up visits will be mandated at 2 weeks, every 3 months for the first year and annually thereafter. Coordinator visits will also occur semi-annually.
The CORAL Study Chair is Lance Dworkin, MD, Brown University, Providence, RI. The CORAL Study Co-Chair is William Henrich, MD, University of Texas, San Antonio, TX. The Principal Investigators of the CORAL Clinical Coordinating Center are Christopher Cooper, MD, University of Toledo Health Science Campus, Toledo OH, and Timothy Murphy, MD, Brown University, Providence, RI.
The Principal Investigator of the Angiographic Core Laboratory is Alan Matsumoto, MD, University of Virginia, Charlottesville, VA. The Principal Investigator of the GFR and Biochemistry Core Laboratory is Michael Steffes, MD, University of Minnesota, Minneapolis, MN. The Principal Investigator of the Economics and Quality of Life Core Laboratory is David Cohen, MD, Mid-America Heart Institute, St. Luke's Hospital, Kansas City, MO. The Principal Investigator of the Data Coordinating Center is Donald Cutlip, MD, Beth Israel Deaconess Medical Center, Boston, MA. For additional information about the CORAL trial, please refer to the CORAL website (link given below).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Either
One or more severe renal artery stenoses by any of the following pathways:
a. Angiographic: greater than or equal to 60% and less than 100% by renal angiogram OR b. Duplex: systolic velocity of greater than 300 cm/sec OR c. Core Lab approved Magnetic Resonance Angiogram (MRA) (refer to the protocol for specific criteria) demonstrating stenosis greater than 80% OR stenosis greater than 70% with spin dephasing on 3D phase contrast MRA OR stenosis greater than 70% and two of the following: i. Ischemic kidney is greater than 1 cm. smaller than contralateral kidney ii. Ischemic kidney enhances less on arterial phase iii. Ischemic kidney has delayed Gd excretion iv. Ischemic kidney hyper-concentrates the urine v. 2-D phase contrast flow waveform shows delayed systolic peak vi. Post-stenotic dilatation d. Clinical index of suspicion combined with a Core Lab approved Computed Tomography Angiography (CTA) demonstrating Stenosis is greater than 80% by visual assessment on high quality CTA Stenosis is greater than 70% on CTA by visual assessment and there are two of the following i. The length of the ischemic kidney is greater than 1 cm. smaller than contralateral kidney ii. Reduced cortical thickness of ischemic kidney iii. Less cortical enhancement of ischemic kidney on arterial phase iv. Post-stenotic dilatation
EXCLUSION CRITERIA:
Presence of a renal artery stenosis not amenable for treatment with a stent, known to be present prior to randomization
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Optimal anti-hypertensive therapy
Drug: Atacand/HCT, Caduet
Stent procedure plus optimal anti-hypertensive therapy
Procedure: GENESISTM Embolic Protection Stent and Angioguard Device (Angioplasty plus stenting)
Drug page: Candesartan cilexetil
Atacand/HCT and caduet or optimal medical therapy for hypertension
Angioplasty plus stenting of the renal artery GENESISTM Embolic Protection Stent and Angioguard Device
Composite Endpoint: Death From Cardiovascular or Renal Causes, Stroke, Myocardial Infarction, Hospitalization for CHF, Progressive Renal Insufficiency, or Permanent Renal Replacement Therapy
Only the first event per participant is included in the composite
Time frame: Measured at every 3 months for the first year and annually thereafter
Cardiovascular or Renal Death
Time frame: Measured at every 3 months for the first year and annually thereafter
Myocardial Infarction
Time frame: Measured at every 3 months for the first year and annually thereafter
Hospitalization for Congestive Heart Failure
Time frame: Measured at every 3 months for the first year and annually thereafter
Stroke
Time frame: Measured at every 3 months for the first year and annually thereafter
30% Reduction of eGFR From Baseline, Persisting for Greater Than or Equal to 60 Days
Time frame: Measured at every 3 months for the first year and annually thereafter
Need for Renal Replacement Therapy
Time frame: Measured at every 3 months for the first year and annually thereafter
| Milestone | Optimal Medical Therapy | Stenting |
|---|---|---|
| Started | 480 | 467 |
| Completed | 472 | 459 |
| Not completed | 8 | 8 |
| Withdrew: Scientific integrity issue | 8 | 8 |
Only the first event per participant is included in the composite
| participants | Optimal Medical Therapy | Stenting |
|---|---|---|
| Composite Endpoint: Death From Cardiovascular or Renal Causes, Stroke, Myocardial Infarction, Hospitalization for CHF, Progressive Renal Insufficiency, or Permanent Renal Replacement Therapy | 169 (0.76 to 1.17) | 161 (0.76 to 1.17) |
| participants | Optimal Medical Therapy | Stenting |
|---|---|---|
| Cardiovascular or Renal Death | 20 | 20 |
| participants | Optimal Medical Therapy | Stenting |
|---|---|---|
| Myocardial Infarction | 27 | 30 |
| participants | Optimal Medical Therapy | Stenting |
|---|---|---|
| Hospitalization for Congestive Heart Failure | 26 | 27 |
| participants | Optimal Medical Therapy | Stenting |
|---|---|---|
| Stroke | 16 | 12 |
| participants | Optimal Medical Therapy | Stenting |
|---|---|---|
| 30% Reduction of eGFR From Baseline, Persisting for Greater Than or Equal to 60 Days | 77 | 68 |
| participants | Optimal Medical Therapy | Stenting |
|---|---|---|
| Need for Renal Replacement Therapy | 3 | 4 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Optimal Medical Therapy | — | 283/472 (60%) | 441/472 (93.4%) |
| Stenting | — | 290/459 (63.2%) | 429/459 (93.5%) |
| Event | Optimal Medical Therapy | Stenting |
|---|---|---|
| Cardiac DisordersCardiac disorders | 117/472 | 128/459 |
| Infections and InfestationsInfections and infestations | 69/472 | 63/459 |
| Nervous System DisordersNervous system disorders | 67/472 | 61/459 |
| Gastrointestinal DisordersGastrointestinal disorders | 42/472 | 57/459 |
| Injury, Poisoning and Procedural ComplicationsInjury, poisoning and procedural complications | 19/472 | 42/459 |
| Musuloskeletal and Connective Tissue DisordersMusculoskeletal and connective tissue disorders | 31/472 | 39/459 |
| General DisordersGeneral disorders | 38/472 | 36/459 |
| Metabolism and Nutrition DisordersMetabolism and nutrition disorders | 28/472 | 19/459 |
| Neoplasms Benign, Malignant and UnspecifiedNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 26/472 | 27/459 |
| Blood and Lymphatic System DisordersBlood and lymphatic system disorders | 11/472 | 16/459 |
| Event | Optimal Medical Therapy | Stenting |
|---|---|---|
| General DisordersGeneral disorders | 261/472 | 251/459 |
| Cardiac DisordersCardiac disorders | 205/472 | 201/459 |
| Injury, Poisoning and Procedural ComplicationsInjury, poisoning and procedural complications | 122/472 | 133/459 |
| InvestigationsInvestigations | 125/472 | 124/459 |
| Blood and Lymphatic System DisordersBlood and lymphatic system disorders | 93/472 | 85/459 |
| Eye DisordersEye disorders | 63/472 | 60/459 |
| Ear and Labyrinth DisordersEar and labyrinth disorders | 24/472 | 32/459 |
| Age, Continuous(years) | Optimal Medical Therapy | Stenting | Total |
|---|---|---|---|
| Mean | 69 ± 9.0 | 69.3 ± 9.4 | 69.15 ± 9.2 |
| Age, Categorical(Participants) | Optimal Medical Therapy | Stenting | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 140 | 127 | 267 |
| >=65 years | 332 | 332 | 664 |
| Sex: Female, Male(Participants) | Optimal Medical Therapy | Stenting | Total |
|---|---|---|---|
| Female | 241 | 225 | 466 |
| Male | 231 | 234 | 465 |
| Region of Enrollment(participants) | Optimal Medical Therapy | Stenting | Total |
|---|---|---|---|
| United States | 387 | 385 | 772 |
The record gives a start of Apr 2004, a primary completion of Sep 2013 and a completion of Sep 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2014, 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Baim Institute for Clinical Research